Source: Eur Respir J 2015; 46: 856-859
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Deschildre Antoine, Marguet Christophe, Langlois Carole, Pin Isabelle, Rittié Jean-Luc, Derelle Jocelyne, Abou Taam Rola, Fayon Michael, Brouard Jacques, Dubus Jean Christophe, Siret Daniel, Weiss Laurence, Pouessel Guillaume, Beghin Laurent, Just Jocelyne. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 2015; 46: 856-859

Member's Comments

No comment yet.

Related content which might interest you: Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018 Year: 2018 Efficacy of the long-term therapy with simbicort in children with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012